An inosamine-idiotrophic mutant, KY11559, which produced no astromicin unless scyllo-inosamine was added to the fermentation medium, was isolated from Micromonospora olivasterospora.
BIOSYNTHESIS
An inosamine-idiotrophic mutant, KY11559, which produced no astromicin unless scyllo-inosamine was added to the fermentation medium, was isolated from Micromonospora olivasterospora.
Biotransformation studies were performed with resting cells of this mutant and compounds assumed to be precursors of 1,4-diaminocyclitol (fortamine).
Scyllo-inosose, scyllo-inosamine and FU-10 were converted to astromicin.
A number of mutants blocked in the biosynthesis of astromicin were developed from M. olivasterospora, and the intermediates accumulated by these mutants were isolated and identified. Twenty-five blocked mutants were classified into 10 groups, based on their complementation patterns by cosynthesis experiments. Further, utilizing these blocked mutants and the isolated compounds, biotransformation analyses were performed.
The results showed that the amination at position 4 in fortamine occurred after formation of the pseudodisaccharide.
Subsequently, the aminosugar and aminocyclitol moieties were aminated, methylated, dehydroxylated, epimerized and acylated to produce astromicin. Thus it was demonstrated that the astromicin biosynthetic pathway has a unique feature which is not found in the biosynthesis of other aminoglycoside antibiotics.
Astromicin (ASTM) is an aminoglycoside
antibiotic produced by Micromonospora olivasterospora1~3 ( Fig. 1 ). ASTM has a broad antibacterial spectrum covering Gram-negative and -positive bacteria and is effective against many aminoglycoside-resistant bacteria 4). Further, this antibiotic is characterized by markedly low ototoxicity5) and nephrotoxicity6) compared with other aminoglycosides.
In antibiotic production, many minor metabolites structurally related to the major one are generally co-produced. In the ASTM fermentation, the number of minor metabolites, the structures of which have so far been determined, amounts to about 50. The authors were able to assume a part of the biosynthetic pathway for ASTM on the basis of biotransformation experiments with the metabolites isolated from mutant strains, as described in the previous report7). 
Materials and Methods
Microorganisms M. olivasterospora KY11520 was used as the parent strain for isolating mutants blocked in the biosynthesis of ASTM. Bacillus subtilis ATCC 6633 was used as the test strain in cosynthesis, bioassay and bioautography. Media ATCC No. 5 agar medium containing glucose 0.6 %, Stabilose K (soluble starch) 0.4 %, Tryptose 0.2%, yeast extract 0.1 %, beef extract 0.1 %, agar 2.0% and FeSO4.7H2O 100 mg/liter was used for isolation of M. olivasterospora mutants, or for sporulation. SK, medium was used as the seed medium. It was composed of Stabilose K 2.0%, glucose 0.5%, yeast extract 0.5%, peptone 0.5%, meat extract 0.3 %, KH2PO, 0.02 %, MgSO2 . 7H4O 0.06 % and CaCO3 0.1 %, and its pH value was 7.6 (before autoclaving). The composition of the fermentation medium was Stabilose K 6 %, soybean meal 2 %, Ebios (dried yeast) 5 %, peptone 0.5 %, KH2P04 0.1 %, K2HPO4 0.3 %, MgSO4.7H2O 0.05 %, NaCl 0.2% and Ca-pantothenate 10 mg/liter. For cosynthesis and the agar piece screening method14), the fermentation medium was diluted two-fold, and 2 % agar was added.
Mutagenesis
The spore suspension was prepared as follows: M. olivasterospora KY11520 was incubated on the ATCC No. 5 agar plate for 3 weeks. After full development of spores was confirmed, spores were scraped off and suspended in 0.1 M Tris-HCl buffer (pH 8.0), 1/15 M phosphate buffer (pH 7.4) or 0.2 M acetate buffer (pH 4.0). After they were washed 4 or 5 times by centrifugation, the suspension was made to contain 1 -2 x 10° spores/ml and treated with mutagens. The mycelia] suspension was prepared by the method reported previously8).
Mutagens used were N-methyl-N'-nitro-N-nitrosoguanidine (NTG), methanesulfonic acid ethyl ester (EMS), methanesulfonic acid methyl ester (MMS), 2-aminopurine (2AP), 8-methoxypsoralen (8-MOP) and sodium nitrite (NaNO2).
Mutagenesis was performed as follows: Treatment with NTG was carried out using the conditions recommended by DELIC et al.9) Treatment with EMS and MMS was performed according to the methods described by ENGEL10) and THOMA14); spores suspended in 1/15 M phosphate buffer were mixed with EMS or MMS to a final concentration of 1-3 % or 0.1-0.3 % and incubated at 35°C for 8 hours under gentle shaking. For treatment with 2AP, spores were suspended in the synthetic medium containing 1,300 Egg of 2AP/ml and incubated with shaking at 30°C for 4 days. Treatment with NaNO2 was performed according to KLANOVA1) ; the spore suspension prepared in 0.2 M acetate buffer (pH 4.0) was mixed with NaNO2 at a final concentration of 1 M and shaken at 35°C for 60 minutes. The reaction was stopped by adding several volumes of 0.1 M Tris-HCl buffer. Irradiation with near ultraviolet light (N-UV) was performed by the methods described by SCOTT et al.12) and TOWNSEND et al.13) Namely, 8-MOP was added to the spore suspension to the final concentration of 100 pg/ml, 5 ml of the suspension was transferred to a Petri dish and irradiated with a black light lamp (Toshiba) from a distance of 20 cm at a dose allowing 1.0-0.1 % of the spores to survive. Irradiation with ultraviolet light was performed according to THOMA'S report14). Irradiation from 60Co was carried THE JOURNAL OF ANTIBIOTICS DEC. 1984 out with spores suspended in 1/15 M phosphate buffer. Spores and mycelia treated with mutagens were spread on ATCC No. 5 agar plates after diluting adequately and incubated at 30°C for about 3 weeks. Each colony developed was picked and examined for production of the antibiotic by the agar piece method15).
Cosynthesis
Cosynthesis was performed according to the methods described by MCCORMICK et al.11) and DELtc et al.11 Blocked mutants were incubated in SK, medium at 30°C for 3 days with shaking. One milliliter of the culture was transferred into 10 ml of fresh SKI medium and incubated at 30°C overnight. Mutant cultures obtained were used for cosynthesis. The schema for cosynthesis tests is illustrated in Fig. 2 .
Biotransformation with Resting Cells8,19) Mutants of M. olivasterospora were incubated in the fermentation medium for 3 days. Mycelia which grew in the medium were harvested, washed 3 times with 0.1 M Tris-HCl buffer (pH 7.5), suspended in the same buffer and used for biotransformation experiments. The reaction mixture containing 150 mg (dry weight) of mycelia and 500~1,000 ltg of substrate in 10 ml of Tris-HCl buffer (pH 7.5) was incubated at 30°C for about 20 hours. Biotransformation products in the reaction mixture were detected by thin-layer chromatography (TLC) and paper chromatography (PPC). TLC was performed by using Merck Silica Gel 60 plates and the lower phase of chloroform -methanol -17 % ammonium hydroxide (I: 1 : 1) as the solvent system. ASTM and its precursors were visualized by the Rydon-Smith reaction20). The amount of each product was determined fluorometrically with a Shimadzu CS-910 double-beam densitometer21). PPC was performed with Toyo No. 51 paper and the lower phase of chloroform -methanol -17 % ammonium hydroxide (1: 1: 1) as the solvent system. Biotransformation products in the reaction mixture were detected by bioautography against Bacillus subtilis ATCC 6633 after PPC.
Identification of Fermentation Products
Antibiotics produced by blocked mutants of M. olivasterospora were purified and identified by the methods reported previously7,19). 
Isolation of Mutants Blocked in the Biosynthesis of Astromicin
Many blocked mutants were isolated from the ASTM producing microorganism, M. olivasterospora.
As shown in Table 1 , a total number of 42,940 colonies were examined, and 182 blocked mutants (0.4 %)
were obtained. Treatment with 60Co and EMS induced these mutants at high frequency. Many mutants were devoid of, or low, in sporulating ability or inferior in growth, and some colonies were mucoid or dwarfish.
Complementation
Pattern between Blocked Mutants Isolated from M. olivasterospora
To determine the blocked step in 29 selected mutants, the cosynthetic ability in pairs of mutants was examined; that is, the ability or inability to produce ASTM in complementation experiments.
When these 29 blocked mutants were tested in 812 pairs for their cosynthetic ability, 25 could be classified into 10 groups according to their complementation patterns (Fig. 3) . Major fermentation products
Isolation of fermentation products from blocked mutants was carried out as follows; 15 liters of fermentation broth of the blocked mutant was adjusted to pH 2.0 with sulfuric acid and stirred for 60 minutes at 30°C and then readjusted to pH 7.0 with sodium hydroxide.
After filtration, the filtrate was applied to a cation-exchange resin IRC-50 (NH4+) column and eluted with I N ammonium hydroxide. The eluate was neutralized with 0.5 N hydrochloric acid and applied to Amberlite CG-50 resin (NH4+) column. The resin was washed with distilled water and eluted with a linear gradient of 0.05 to 0.5 N ammonium hydroxide. Fractions were monitored using silica gel TLC. Similar fractions were combined and lyophilized to yield crude preparations. Each preparation was further chromatographed on a silica gel column and purified.
Mutants
From each of the 10 groups of mutants classified by the cosynthesis experiments, a representative strain was chosen for isolation and identification of its major products. They are shown in Table 2 . It was found by TLC that KY11558 accumulated scyllo-inosamine. From KY11554, two major products, FU-10 and FOX-2, were isolated. The results of cosynthesis experiments show that the mutant KY11559 serves as a convertor with mutants of all other groups imply that KY11559 is blocked at the earliest step in the ASTM biosynthetic pathway. Since this mutant requires inosamine for ASTM production, it was presumed to lack the ability to biosynthesize fortamine, the aminocyclitol moiety of ASTM. Thus, KY11559 was classified as an "inosamine (ISM)-idiotroph".
Biotransformation of various cyclitols was carried out with the ISM-idiotroph, KY11559. As shown in Table 4 On the basis of the experimental findings described so far, the authors propose the extended biosynthetic pathway shown in Fig. 4 for ASTM.
Discussion
ASTM is a pseudodisaccharide aminoglycoside of a new type. Sporaricin22), istamycin23) and dactimicin24) are recently found to be aminoglycosides belonging to the same group. These antibiotics are closely akin in chemical structure, and it has been interesting problem to know the biosynthetic origin of these antibiotics. In the previous paper7), part of the pathway for ASTM biosynthesis was deduced from the results of biotransformation experiments. In the present study, the ASTM biosynthetic pathway was established in more detail by isolating many blocked mutants and investigating their properties. Of the variety of mutagens tried, y-rays and EMS induced blocked mutants and auxotrophic mutants with high frequency (0.8-1.0%).
Treatment with 60CO, EMS and MMS (lower in frequency of mutant isolation) induced some mutants blocked at different steps on the ASTM biosynthetic pathway. Most of mutants obtained by N-UV and UV irradiation accumulated FU-10 (mutants blocked at step C in Fig. 3 ). THOMA14) reported that EMS and MMS were effective as mutagens with Penicillium chrysogenum (penicillin-producer), but not practical for Streptomyces. Our study demonstrated that 7--rays and alkylating agents were suitable mutagens for M. olivasterospora.
Mutants blocked in the pathway of antibiotic biosynthesis have recently been called idiotrophs25), and their practical usefulness has been recognized. Studies with idiotrophs have contributed to increased knowledge of antibiotic biosythesis8,19,26~28,35) as well as to the production of new antibiotics25,29~34). For instance, 2-deoxystreptamine-(DOS)-idiotrophs used to study aminoglycoside biosynthesis35) have contributed to the elucidation of DOS biosynthesis in M. purpurea31), M. sagamiensis19) and B. circulans28). There is no previous information on the biosynthesis of the ASTM The isolation of an inosamine idiotroph of M. olivasterospora, KY11559, and the results of bioconversion and cosynthesis experiments with this mutant indicate that fortamine is formed from scyllo-inosamine (via scyllo-inosose), which is already attached to D-glucosamine in FU-10 and is then aminated at position 4. Part of this biosynthetic route, that is, -*scyllo-inosose--*scyllo-inosamine, is seen in streptidine biosynthesis34-381. Though it has not been known whether scyllo-inosose is synthesized from myo-inositol in M. olivasterospora, fortamine and streptidine are most likely formed by a partially common route.
In the case of kanamycin, gentamicin, sagamicin and butirosin, it has been known that 1,3-diaminocyclitol (DOS) itself is incorporated into the antibiotics19, 28, 31, 35) A similar process has been reported for incorporation of the cyclitol (streptidine) in streptomycin biosynthesis36~36). However, in the case of ASTM, the amination at position 4 introducing the second amino group of fortamine occurred after formation of the disaccharide. The results of biotransformations with the ISM-idiotroph (Table 4 ) and accumulation of FU-10 and scyllo-inosamine by KY11554 and KY11558, respectively, strongly supported this conclusion.
SU-1, 2 and 3 are antibiotics having a monoaminocyclitol33,34). These antibiotics are 1-deamino-1-hydroxyl derivatives of gentamicin C2, -C1a and sagamicin, respectively, and are produced by mutants of M. sagamiensis. KASE33) et al. have reported that, instead of DOS, 2-deoxy-scyllo-inosamine (DOI) was incorporated into the aminocyclitol moiety. Biosyntheses of ASTM and of these antibiotics differ in the point that the monoaminocyclitol precursor of ASTM is converted into a diaminocyclitol after forming a disaccharide.
In addition to this unique feature in the introduction of amino functions, the biosynthesis of fortamine is characterized by further modification of the aminocyclitol moiety after psuedodisaccharide formation. The only known example of the modification of an aminocyclitol unit after combination with other subunits in the biosynthesis of aminoglycoside antibiotics is the transfer of an acyl group to the NH., group at position 1 in butirosin biosynthesis28). In ASTM biosynthesis, by contrast, 5 conversions viz methylation at positions 3 and 4, glycylation at position 4 and epimerization at positions 3 and 4, occur as a series of reactions subsequent to formation of the amino functions at positions 1 and 4.
Besides Micromonospora1~3), Streptomyces23), Saccharopolyspora22) and Dactylosporangium24) are known to produce antibiotics of the ASTM group. It would be very interesting to elucidate whether these related antibiotics are synthesized by a common biosynthetic route.
